Triangle Biotechnology
Triangle Biotechnology is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Triangle Biotechnology.
Triangle Biotechnology is a company.
Key people at Triangle Biotechnology.
Triangle Biotechnology Inc. is a biotechnology company founded in 2017 that develops innovative sonication reagents and systems to simplify and accelerate life science sample preparation, particularly for next-generation sequencing (NGS), epigenetic assays like ChIP, and cell lysis.[1][2][5] Its flagship product, RapidShear, is a cavitation-enhancing reagent for efficient gDNA fragmentation, serving researchers and labs facing time-consuming, costly processes in nucleic acid extraction and processing.[1][2][5] The company targets challenges in handling tough biological samples, such as resilient microbes, with affordable, high-throughput solutions that improve DNA yield—demonstrating 6-100x better extraction from models like Mycobacterium smegmatis compared to commercial kits—while maintaining a small team (<25 employees) and revenue under $5M, bolstered by SBIR funding including a $300K Phase I grant.[2][4]
Triangle Biotechnology emerged from the University of Arizona's innovation ecosystem, with key inventors Mark Borden, Paul Dayton, Terry Matsunaga, and Paul Sheeran, experts in acoustics and nanotechnology, spinning out technologies for acoustic processing of biological samples.[3] Founded in 2017, the company relocated its headquarters to Research Triangle Park, North Carolina (6 Davis Drive, Suite 827), positioning itself in a biotech hub to scale operations.[1] Early traction came from developing RapidShear for gDNA shearing in NGS and expanding into chromatin shearing for ChIP and cell lysis, fueled by SBIR grants targeting culture-free microbial enrichment for antimicrobial resistance diagnostics—a pivotal moment that validated their nanodroplet tech for hard-to-lyse pathogens like Mycobacterium tuberculosis models.[4][5]
Triangle Biotechnology rides the NGS and precision diagnostics wave, where demand for rapid, culture-free microbial detection addresses 15 million annual deaths from bacterial/fungal diseases, outpacing slow traditional tests.[4] Timing aligns with portable sonication and NAT advancements, as falling sequencing costs amplify needs for upstream sample prep efficiency—market forces like antimicrobial resistance (e.g., TB) and epigenetic research favor their acoustic disruption tech.[1][4][5] By productizing kits for hard-to-lyse samples, they lower barriers to broad NAT adoption, influencing the ecosystem through SBIR-validated platforms that could integrate with point-of-care devices, boosting startup innovation in biotech tools.[4]
Triangle Biotechnology is poised to expand its reagent platform via Phase II SBIR (targeting 12 pathogens, clinical validation, and portable sonicator protocols by Y3), potentially launching diagnostic kits that transform TB and resistance testing.[4] Trends like AI-driven NGS analysis and decentralized diagnostics will amplify their edge in sample prep, with growth via collaborations scaling from <25 employees to broader market penetration.[2][5] Their influence may evolve from niche NGS enabler to key player in global health tech, humanizing research acceleration from university labs to frontline impact—echoing their mission to make complex prep revolutionary and routine.[1][5]
Key people at Triangle Biotechnology.